Malignant mesothelioma is a rare neoplasm which could be favored by an hereditary predisposing factor. So far, malignant mesothelioma have never been described in patients with hereditary diseases of the connective tissue. Here, we report some cases of mesothelioma affecting subjects who were not exposed to inhalation of asbestos. One of these subjects was affected by Ehlers-Danlos syndrome, whereas in two brothers, mesothelioma was associated with Marfan’s syndrome. The observation of the same histologic subtype of mesothelioma in two brothers and the coexistence of two pathologic conditions of mesodermal origin indicate the presence of hereditary factors predisposing to the cancerogenic action of even small amounts of asbestos. Structural alterations of collagen and primary immunodeficiency may represent the host factor inducing development of the neoplasm. We conclude that the association between these rare disorders of the connective tissue and mesothelioma may not be coincidental, but could be the result of the exposition to small amounts of asbestos in predisposed individuals.

Keywords:
Malignant mesothelioma, Marfan’s syndrome, Ehlers-Danlos syndrome
1.
Brian L, Anaclerio M, Rossi P: Tipi Fisici e Temperamenti Umani. Padova, Piccin, 1987.
2.
Bhalla AK, Williams PL: Clinician’s Illustrated Dictionary of Rheumatology. London, Science Press, 1989.
3.
Linch HT, Katz D, Markvicka SE: Familial mesothelioma: Review and family study. Cancer Genet Cytogenet 1985;15:25–35.
4.
Martensson G, Larsson S, Zettergren L: Malignant mesothelioma in two pairs of siblings: Is there a hereditary predisposing factor? Eur J Respir Dis 1984;65:79–84.
5.
Krousel T, Garcas N, Rothschild H: Familial clustering of mesothelioma: A report on three affected persons in one family. Am J Prev Med 1986;2:186–188.
6.
Li FP, Lokich J, Lapey J, Neptune WB, Wilkins EW Jr: Familial mesothelioma after intense asbestos exposure at home. JAMA 1978;240–467.
7.
Muñoz L, Guzman J, Ponce de Leon S, Mutchinick O, Arista J, Vazquez J: Familial malignant pleural mesothelioma. Report of 3 cases. Rev Invest Clin 1988;40:413–417.
8.
Browne K: Asbestos related mesothelioma: Epidemiological evidence for asbestos as a promoter. Arch Environ Health 1983;8:261–266.
9.
Ferguson GC, Watson H: Mesothelioma due to domestic exposure to asbestos. BMJ 1984;288:1654.
10.
Dawson A, Gibbs A, Browne K, Pooley F, Griffiths M: Familial mesothelioma. Cancer 1992;70(5):1183–1187.
11.
McDonald JC, McDonald AD: Mesothelioma: Is there a background? International Conference Mesothelial Cells and Mesothelioma. Past, Present and Future, Paris, September 30, 1991.
12.
Morinaga K, Kohyama N, Yokoyama K, Yasui Y, Hara I, Saki M, Suzuki Y, Sera Y: Asbestos fibre contents of lungs with mesotheliomas in Osaka, Japan: A preliminary report. IARC Sci Publ 1989;90:438–443.
13.
Oels HC, Harrison EG, Carr DT, Bernatz PE: Diffuse malignant mesothelioma of the pleura. A review of 37 cases. Chest 1971;60:564–570.
14.
Mossman BT, Gee JB: Asbestos related diseases. N Engl J Med 1989;320(26):1721–1730.
15.
Mossman BT, Gee JB, Gignon J, Corn M, Seaton A: Asbestos: Scientific developments and implications for public policy. Science 1990;247(4940):294–301.
16.
Pyeritz RE, McKusic VA: The Marfan syndrome: Diagnosis and management. N Engl J Med 1979;300(14):772–777.
17.
Golden RL, Lakin H: The forme fruste in the Marfan’s syndrome. N Engl J Med 1959;260(16):797–801.
18.
Sensenig DM, La Marche P: Marfan’s syndrome and spontaneous pneumothorax. Am J Surg 1980;139:602–604.
19.
Wilner HI, Finby N: Skeletal manifestations in the Marfan syndrome. JAMA 1964;187(7):490–495.
20.
Snyder LH: The Principles of Heredity, ed 3. Boston, Heath, 1946.
21.
Milewicz DM, Grossfield J, Cao SN, Kielty C, Covitz W, Jewett T: A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest 1995;95(5):2373–2378.
22.
Encyclopédie médico-chirurgicale (Dérmatologie) vol II, 1988, p 9.
23.
Marsh JP, Greenslade R, Holley J, Gabrielson E, Lechner J, Mossman BT: Sensitivity of human and rat pleural mesothelial cells to asbestos and oxidants. International Conference Mesothelial Cells and Mesothelioma. Past, Present and Future, Paris, September 30, 1991.
24.
Zulueta JJ, Bloom SM, Rozansky MI, White AC: Lung cancer in patients with bullous disease. Am J Respir Crit Care Med 1996;154:519–522.
25.
Hull MT, Warfel KA: Ultrastructure of abnormal collagen in human tumours. Ultrastruct Pathol 1986, 10:293–301.
26.
Harley VR, Chan D, Rogers JG, Cole WG: Marfan syndrome: Absence of type I or III collagen structural defects in 25 patients. J Inherit Metab Dis 1990;13(2):219–226.
27.
Antony VB, Godbey S, Sparks I, Hott J: Repair of the injured pleura: Mesothelial cell regulation of pleural fibroblast proliferation, directed migration, and collagen synthesis. International Conference Mesothelial Cells and Mesothelioma. Past, Present and Future, Paris, September 30, 1991.
28.
Delahaye M, de Jong AA, Versnel MA, Hoogsteden HC, Teeling P, van der Kwast TH: Cytopathology of malignant mesothelioma. Reappraisal of the diagnostic value of collagen cores. Cytopathology 1990;1:137–145.
29.
Samsygin SA, Dolgine EN, Luk’ianov SV, Rudakov SS: Immunologic disorders in children with developmental thoracic defects. Khirurgiia 1990;8:85–89.
30.
Penn I: Immunodepressione in Oncologia. Excerpta Medica. Amsterdam, Elsevier, 1991.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.